Bio-Rad Laboratories Net Profit Margin 2006-2019 | BIO
Current and historical net profit margin for Bio-Rad Laboratories (BIO) from 2006 to 2019. Net profit margin can be defined as net Income as a portion of total sales revenue. Bio-Rad Laboratories net profit margin for the three months ending September 30, 2019 was .
| Bio-Rad Laboratories Net Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Net Income | Net Margin |
| 2019-09-30 | $2.31B | $0.38B | 16.31% |
| 2019-06-30 | $2.29B | $0.90B | 39.49% |
| 2019-03-31 | $2.29B | $0.57B | 25.00% |
| 2018-12-31 | $2.29B | $0.37B | 15.94% |
| 2018-09-30 | $2.29B | $1.28B | 55.67% |
| 2018-06-30 | $2.28B | $1.03B | 45.12% |
| 2018-03-31 | $2.21B | $0.77B | 34.67% |
| 2017-12-31 | $2.16B | $0.12B | 5.65% |
| 2017-09-30 | $2.11B | $0.02B | 0.76% |
| 2017-06-30 | $2.09B | $0.01B | 0.58% |
| 2017-03-31 | $2.10B | $0.03B | 1.19% |
| 2016-12-31 | $2.07B | $0.03B | 1.21% |
| 2016-09-30 | $2.07B | $0.09B | 4.55% |
| 2016-06-30 | $2.03B | $0.09B | 4.58% |
| 2016-03-31 | $2.02B | $0.10B | 5.10% |
| 2015-12-31 | $2.02B | $0.11B | 5.40% |
| 2015-09-30 | $2.05B | $0.10B | 4.98% |
| 2015-06-30 | $2.11B | $0.10B | 4.60% |
| 2015-03-31 | $2.14B | $0.10B | 4.72% |
| 2014-12-31 | $2.18B | $0.09B | 4.14% |
| 2014-09-30 | $2.18B | $0.08B | 3.72% |
| 2014-06-30 | $2.15B | $0.06B | 2.88% |
| 2014-03-31 | $2.14B | $0.07B | 3.03% |
| 2013-12-31 | $2.13B | $0.08B | 3.66% |
| 2013-09-30 | $2.10B | $0.09B | 4.33% |
| 2013-06-30 | $2.10B | $0.14B | 6.72% |
| 2013-03-31 | $2.08B | $0.15B | 7.39% |
| 2012-12-31 | $2.07B | $0.17B | 7.97% |
| 2012-09-30 | $2.05B | $0.18B | 8.90% |
| 2012-06-30 | $2.06B | $0.19B | 8.97% |
| 2012-03-31 | $2.08B | $0.18B | 8.53% |
| 2011-12-31 | $2.07B | $0.18B | 8.63% |
| 2011-09-30 | $2.06B | $0.19B | 9.09% |
| 2011-06-30 | $2.01B | $0.19B | 9.24% |
| 2011-03-31 | $1.96B | $0.18B | 9.39% |
| 2010-12-31 | $1.93B | $0.19B | 9.65% |
| 2010-09-30 | $1.89B | $0.16B | 8.26% |
| 2010-06-30 | $1.88B | $0.15B | 7.99% |
| 2010-03-31 | $1.84B | $0.15B | 8.17% |
| 2009-12-31 | $1.78B | $0.15B | 8.13% |
| 2009-09-30 | $1.74B | $0.10B | 5.70% |
| 2009-06-30 | $1.72B | $0.09B | 5.12% |
| 2009-03-31 | $1.74B | $0.09B | 5.34% |
| 2008-12-31 | $1.76B | $0.09B | 5.05% |
| 2008-09-30 | $1.78B | $0.11B | 6.14% |
| 2008-06-30 | $1.67B | $0.11B | 6.51% |
| 2008-03-31 | $1.56B | $0.09B | 5.89% |
| 2007-12-31 | $1.46B | $0.09B | 6.36% |
| 2007-09-30 | $1.35B | $0.10B | 7.29% |
| 2007-06-30 | $1.31B | $0.09B | 7.10% |
| 2007-03-31 | $1.29B | $0.10B | 7.68% |
| 2006-12-31 | $1.27B | $0.10B | 8.08% |
| 2006-09-30 | $1.24B | $0.10B | 8.00% |
| 2006-06-30 | $1.22B | $0.09B | 7.57% |
| 2006-03-31 | $1.19B | $0.08B | 6.56% |
| 2005-12-31 | $1.18B | $0.08B | 6.78% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $10.615B | $2.290B |
| Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company's products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $152.706B | 27.85 |
| Medtronic (MDT) | Ireland | $152.160B | 21.02 |
| Stryker (SYK) | United States | $75.917B | 25.53 |
| Boston Scientific (BSX) | United States | $62.848B | 29.66 |
| Baxter (BAX) | United States | $42.866B | 25.99 |
| Essilor Luxottica (ESLOY) | France | $34.245B | 0.00 |
| Zimmer Biomet Holdings (ZBH) | United States | $30.456B | 19.11 |
| Terumo (TRUMY) | Japan | $27.092B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $25.394B | 0.00 |
| Coloplast (CLPBY) | Denmark | $24.797B | 38.27 |
| ResMed (RMD) | United States | $22.090B | 40.75 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $20.228B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $19.217B | 0.00 |
| Insulet (PODD) | United States | $10.859B | 516.62 |
| William Demant Holdings (WILYY) | Denmark | $7.675B | 0.00 |
| DiaSorin S.p.A (DSRLF) | Italy | $7.616B | 0.00 |
| Perrigo (PRGO) | Ireland | $7.340B | 13.69 |
| Hill-Rom Holdings (HRC) | United States | $7.289B | 21.49 |
| Canopy Growth (CGC) | Canada | $7.208B | 0.00 |
| Haemonetics (HAE) | United States | $5.904B | 39.89 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $5.472B | 0.00 |
| GN STORE NORD (GNNDY) | Denmark | $5.276B | 0.00 |
| NuVasive (NUVA) | United States | $3.947B | 31.08 |
| ICU Medical (ICUI) | United States | $3.686B | 24.03 |
| Neogen (NEOG) | United States | $3.583B | 59.96 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $3.293B | 0.00 |
| Hutchison China MediTech (HCM) | Hong Kong, SAR China | $3.073B | 0.00 |
| Quidel (QDEL) | United States | $2.950B | 27.99 |
| Aurora Cannabis (ACB) | Canada | $2.865B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $2.750B | 0.00 |
| National Vision Holdings (EYE) | United States | $2.495B | 56.30 |
| Cardiovascular Systems (CSII) | United States | $1.607B | 0.00 |
| Aphria (APHA) | $1.384B | 0.00 | |
| InMode (INMD) | Israel | $1.242B | 0.00 |
| AtriCure (ATRC) | United States | $1.206B | 0.00 |
| VAREX IMAGING (VREX) | United States | $1.199B | 24.01 |
| TG Therapeutics (TGTX) | United States | $1.006B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.969B | 18.14 |
| NanoString Technologies (NSTG) | United States | $0.912B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.820B | 31.41 |
| Lantheus Holdings (LNTH) | United States | $0.795B | 19.86 |
| LeMaitre Vascular (LMAT) | United States | $0.711B | 39.98 |
| PetIQ (PETQ) | United States | $0.695B | 16.96 |
| Quanterix (QTRX) | United States | $0.676B | 0.00 |
| Omeros (OMER) | United States | $0.667B | 0.00 |
| HEXO (HEXO) | $0.576B | 0.00 | |
| Cerus (CERS) | United States | $0.560B | 0.00 |
| Surmodics (SRDX) | United States | $0.552B | 57.38 |
| MacroGenics (MGNX) | United States | $0.518B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.497B | 29.80 |
| Meridian Bioscience (VIVO) | United States | $0.413B | 14.21 |
| Organigram Holdings (OGI) | Canada | $0.405B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.396B | 28.68 |
| Owens & Minor (OMI) | United States | $0.346B | 12.81 |
| BioLife Solutions (BLFS) | United States | $0.320B | 130.58 |
| Zynex (ZYXI) | United States | $0.305B | 34.48 |
| Bovie Medical (APYX) | United States | $0.276B | 0.00 |
| Neptune Wellness Solutions (NEPT) | Canada | $0.274B | 0.00 |
| United Health Products (UEEC) | United States | $0.251B | 0.00 |
| Vapotherm (VAPO) | United States | $0.244B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.238B | 25.08 |
| Repro-Med Systems (KRMD) | United States | $0.228B | 0.00 |
| Green Organic Dutchman Holdings (TGODF) | Canada | $0.172B | 0.00 |
| Liberty Health Sciences (LHSIF) | Canada | $0.171B | 0.00 |
| Female Health (VERU) | United States | $0.157B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.142B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.136B | 0.00 |
| Fonar (FONR) | United States | $0.130B | 9.18 |
| MTech Acquisition (KERN) | United States | $0.128B | 0.00 |
| Chimerix (CMRX) | United States | $0.110B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.093B | 0.00 |
| United-Guardian (UG) | United States | $0.091B | 22.93 |
| Chembio Diagnostics (CEMI) | United States | $0.078B | 0.00 |
| Nephros (NEPH) | United States | $0.066B | 0.00 |
| MRI Interventions (MRIC) | United States | $0.062B | 0.00 |
| Surface Oncology (SURF) | United States | $0.049B | 0.00 |
| ImmuCell (ICCC) | United States | $0.037B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.024B | 0.00 |
| Senestech (SNES) | United States | $0.016B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.015B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.014B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.012B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.006B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.004B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.002B | 0.00 |
